Valley National Advisers Inc. Has $1.70 Million Stock Holdings in Cencora, Inc. (NYSE:COR)

Valley National Advisers Inc. grew its holdings in Cencora, Inc. (NYSE:COR) by 34,181.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 7,542 shares of the company’s stock after purchasing an additional 7,520 shares during the period. Valley National Advisers Inc.’s holdings in Cencora were worth $1,697,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of COR. New Millennium Group LLC bought a new stake in Cencora during the 2nd quarter worth $26,000. TCTC Holdings LLC bought a new stake in Cencora during the 1st quarter worth $29,000. TFO Wealth Partners LLC bought a new stake in Cencora during the 1st quarter worth $30,000. LRI Investments LLC bought a new stake in Cencora during the 1st quarter worth $31,000. Finally, MFA Wealth Advisors LLC bought a new stake in Cencora during the 2nd quarter worth $30,000. Institutional investors own 97.52% of the company’s stock.

Insider Buying and Selling at Cencora

In related news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the transaction, the insider now owns 19,980,000 shares of the company’s stock, valued at $4,806,388,800. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the completion of the transaction, the insider now directly owns 19,980,000 shares of the company’s stock, valued at $4,806,388,800. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction dated Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the transaction, the chairman now directly owns 285,088 shares of the company’s stock, valued at $67,223,750.40. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 4,461,153 shares of company stock valued at $1,073,075,720 over the last quarter. 15.80% of the stock is owned by company insiders.

Cencora Stock Down 0.3 %

NYSE COR opened at $234.47 on Friday. The company has a fifty day moving average of $232.15 and a two-hundred day moving average of $230.81. The company has a quick ratio of 0.55, a current ratio of 0.89 and a debt-to-equity ratio of 3.93. The firm has a market capitalization of $46.77 billion, a price-to-earnings ratio of 25.65, a PEG ratio of 1.40 and a beta of 0.44. Cencora, Inc. has a 52 week low of $182.75 and a 52 week high of $247.66.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, beating analysts’ consensus estimates of $3.18 by $0.16. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The business had revenue of $74.20 billion for the quarter, compared to analyst estimates of $73.32 billion. During the same period in the prior year, the company earned $2.92 earnings per share. The company’s revenue was up 10.8% on a year-over-year basis. On average, analysts predict that Cencora, Inc. will post 13.63 earnings per share for the current year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 9th were given a $0.51 dividend. This represents a $2.04 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date was Friday, August 9th. Cencora’s payout ratio is 22.32%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Wells Fargo & Company boosted their price objective on Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 1st. Leerink Partners reduced their price target on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research report on Monday, October 7th. Evercore ISI reduced their price target on Cencora from $270.00 to $250.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Robert W. Baird reduced their price target on Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a research report on Friday, September 6th. Finally, Bank of America reiterated a “neutral” rating and issued a $245.00 price target (down previously from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $259.44.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.